Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Blakemore

Showing results (191-200 of 200) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 200 results.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
Journal of Medicinal Chemistry|April 29, 2025
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9Matthew H Daniels, Jennifer Castro, Young-Tae Lee, et al.
Communications Biology|April 9, 2025
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3',5'-bisphosphate as a potent enzyme inhibitorGordon J Lockbaum, Maureen M Lynes, Sophie A Shen, et al.
Cancer Research|November 26, 2024
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch RepairJennifer Castro, Matthew H Daniels, David Brennan, et al.
Leukemia|February 5, 2020
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trialStuart J Blakemore, Ruth Clifford, Helen Parker, et al.
Blood Advances|August 23, 2019
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trialsTomasz K Wojdacz, Harindra E Amarasinghe, Latha Kadalayil, et al.
Blood|December 17, 2013
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapyGeorge Mulligan, David I Lichter, Alessandra Di Bacco, et al.
Blood|December 18, 2015
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutationsViktor Ljungström, Diego Cortese, Emma Young, et al.
Leukemia|November 29, 2016
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemiaE Young, D Noerenberg, L Mansouri, et al.
Cancer Cell|June 13, 2025
CSF1R<sup>+</sup> myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphomaDavid Stahl, Philipp Gödel, Hyatt Balke-Want, et al.
Pageof 20

Showing results (191-200 of 200) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 200 results.
Blood|May 5, 2018
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemiaEytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, et al.
Journal of Medicinal Chemistry|April 29, 2025
Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9Matthew H Daniels, Jennifer Castro, Young-Tae Lee, et al.
Communications Biology|April 9, 2025
Characterization of exoribonuclease XRN1 as a cancer target and identification of adenosine-3',5'-bisphosphate as a potent enzyme inhibitorGordon J Lockbaum, Maureen M Lynes, Sophie A Shen, et al.
Cancer Research|November 26, 2024
A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch RepairJennifer Castro, Matthew H Daniels, David Brennan, et al.
Leukemia|February 5, 2020
Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trialStuart J Blakemore, Ruth Clifford, Helen Parker, et al.
Blood Advances|August 23, 2019
Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trialsTomasz K Wojdacz, Harindra E Amarasinghe, Latha Kadalayil, et al.
Blood|December 17, 2013
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapyGeorge Mulligan, David I Lichter, Alessandra Di Bacco, et al.
Blood|December 18, 2015
Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutationsViktor Ljungström, Diego Cortese, Emma Young, et al.
Leukemia|November 29, 2016
EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemiaE Young, D Noerenberg, L Mansouri, et al.
Cancer Cell|June 13, 2025
CSF1R<sup>+</sup> myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphomaDavid Stahl, Philipp Gödel, Hyatt Balke-Want, et al.
Pageof 20